Second Sight Medical Products (EYES) Gains Daily Media Sentiment Score of 0.31

Second Sight Medical Products (EYES) Gains Daily Media Sentiment Score of 0.31

Headlines about Second Sight Medical Products (NASDAQ:EYES) have been trending positive recently, AlphaOne Sentiment reports. AlphaOne, a division of Accern, rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a news impact score of 0.31 on AlphaOne’s scale. AlphaOne also gave news coverage about the medical device company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Alpha One Sentiment’s rankings:

Second Sight Medical Products (NASDAQ:EYES) traded down 0.8246% during trading on Monday, reaching $1.1306. 130,577 shares of the company’s stock traded hands. The firm’s market cap is $63.73 million. Second Sight Medical Products has a 12 month low of $1.06 and a 12 month high of $4.75. The firm has a 50 day moving average price of $1.17 and a 200-day moving average price of $1.57.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings results on Wednesday, May 3rd. The medical device company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.04. Second Sight Medical Products had a negative return on equity of 121.31% and a negative net margin of 502.22%. The business had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.32 million. On average, analysts forecast that Second Sight Medical Products will post ($0.52) earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded shares of Second Sight Medical Products from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th.

In other Second Sight Medical Products news, Director Gregg Williams purchased 4,000,000 shares of the business’s stock in a transaction on Friday, April 7th. The shares were purchased at an average cost of $1.00 per share, with a total value of $4,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 34.70% of the company’s stock.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:EYES”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment